Biohaven price target raised to $66 from $36 at Piper Sandler

Piper Sandler raised the firm’s price target on Biohaven to $66 from $36 and keeps an Overweight rating on the shares after layering BHV-1300 — the company’s novel IgG degrader — into its model. The firm anticipates positive FIH data this quarter and a proposed commercial roll-out with a partner starting in 2029. Piper remains a buyer of the stock.